<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2010-610</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-295</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Проблемы профилактики и лечения глюкокортикоидного остеопороза</article-title><trans-title-group xml:lang="en"><trans-title>GLUCOCORTICOID-INDUCED OSTEOPOROSIS: PATHOGENESIS, PREVENTION, TREATMENT</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баранова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Baranova</surname><given-names>Irina Aleksandrovna</given-names></name></name-alternatives><email xlink:type="simple">iribaranova@yandex.ru &amp;lt;mailto:iribaranova@yandex.ru&amp;gt;</email></contrib></contrib-group><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>20</day><month>06</month><year>2010</year></pub-date><volume>4</volume><issue>2</issue><issue-title>№2 (2010)</issue-title><fpage>94</fpage><lpage>99</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Баранова И.А., 2010</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="ru">Баранова И.А.</copyright-holder><copyright-holder xml:lang="en">Baranova I.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/295">https://mrj.ima-press.net/mrj/article/view/295</self-uri><abstract><p>Остеопороз (ОП) является серьезной проблемой для больных, длительно принимающих глюкокортикоиды. За последние 20 лет накоплено большое количество знаний об эпидемиологии заболевания, появились препараты с доказанной эффективностью для его профилактики и лечения. Однако большое количество исследований свидетельствует о серьезных недостатках в помощи больным глюкокортикоидным ОП, что требует действенных мер для приведения реального уровня его профилактики и лечения в соответствие требованиям современных клинических рекомендаций</p></abstract><trans-abstract xml:lang="en"><p>Osteoporosis (OP) is a serious problem to patients who have long taken glucocorticoids. In the past two decade, much knowledge has been accumulated about the epidemiology of the disease and drugs with proven efficacy for its prevention and treatment have emerged. However, a large number of studies suggest that there is a serious shortage in care to patients with glucocorticoid-induced OP, which calls for effective measures to bring the real level of its prevention and treatment in compliance with the current clinical guidelines</p></trans-abstract><kwd-group xml:lang="ru"><kwd>глюкокортикоидный остеопороз</kwd><kwd>профилактика</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>glucocorticoid-induced osteoporosis</kwd><kwd>prevention</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
